A repairing and soothing composition, a repairing and soothing product, its preparation method and application
By combining mussel extract with recombinant collagen in a specific ratio, this product addresses the challenge of simultaneously repairing the skin barrier in a vicious cycle of damage and inflammation, as demonstrated by existing skincare products. This results in rapid and long-lasting anti-inflammatory and barrier repair effects, making it suitable for various skincare scenarios.
Patent Information
- Application Number
- CN202611338131.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-31
- Publication Date
- 2026-11-10
AI Technical Summary
Existing skin care products often have only one function when dealing with the vicious cycle of barrier damage and inflammatory response. They cannot simultaneously achieve anti-inflammatory and repair effects, resulting in slow onset of action and easy recurrence of problems, making it difficult to meet the comprehensive care needs of complex damaged conditions.
By combining mussel extract and recombinant collagen at a specific mass ratio (12~300:1), the synergistic effect on inflammatory response and barrier damage is achieved. Mussel extract inhibits the release of inflammatory factors, while recombinant collagen promotes cell adhesion and migration, thus simultaneously blocking the vicious cycle.
It achieves rapid and lasting effects that address both the symptoms and the root cause, effectively inhibiting the release of inflammatory factors and promoting skin barrier reconstruction, thus broadening the product's application scope and making it suitable for complex care scenarios ranging from daily soothing to deep repair.
Smart Images

Figure CN123058985A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of cosmetics and topical skin preparations, and more specifically, to a repairing and soothing composition, a repairing and soothing product, a method for preparing the same, and its application. Background Technology
[0002] As the first physiological defense line of the human body in contact with the external environment, the skin plays a vital role in resisting the invasion of harmful external substances and maintaining internal moisture balance. With increased external environmental stimuli and changes in internal physiological factors, the skin is highly susceptible to barrier damage. Once the barrier is damaged, it is often accompanied by and triggers a local inflammatory response, manifesting as redness, stinging, and other sensitive symptoms. This "barrier damage" and "inflammatory response" are closely linked in pathological mechanisms and exacerbate each other, forming a vicious cycle. Therefore, how to effectively repair and soothe damaged skin and break this vicious cycle has always been a key focus of continuous research and attention in the field.
[0003] In diseases related to abnormal skin / mucosal barrier function (such as atopic dermatitis, psoriasis, rosacea, and sensitive skin syndrome), the complexity of the vicious cycle of "inflammation-barrier damage" is manifested in the fact that inflammatory mediators (such as TNF-α, IL-6, and IL-1β) not only directly mediate local immune responses but also hinder the barrier's self-repair capacity by downregulating barrier repair-related cellular behaviors (especially cell adhesion and migration). Persistent barrier defects further activate local immune cells, releasing more inflammatory factors, forming a positive feedback loop of "increased inflammatory factors → decreased adhesion / migration capacity → delayed barrier repair → further increase in inflammatory factors." While simple anti-inflammatory treatment can temporarily reduce inflammatory factor levels, it often fails to promote or even inhibits cell adhesion and migration, leading to relapse after drug withdrawal. Conversely, while simple repair promotion can enhance cell migration, it cannot control the continuous damage of inflammatory factors to the adhesion process, resulting in the continued predicament of "protracted and recurrent" cases in clinical practice.
[0004] Currently, to address the aforementioned skin problems, the industry has developed a variety of topical products or active ingredients. Existing technological solutions typically employ different active ingredients to target specific skin issues. For example, in areas focusing on repair, large molecules such as collagen are often used, primarily by forming a physical protective film on the skin surface or providing some moisturizing effect to aid in barrier repair. In areas focusing on soothing and anti-inflammatory effects, traditional plant extracts or single, conventional anti-inflammatory ingredients are often used to temporarily suppress the release of inflammatory signals and reduce external reactions such as redness and swelling.
[0005] However, existing single-ingredient or conventional combinations have revealed significant limitations in practical applications. On the one hand, most existing formulations have a single efficacy; ingredients focusing on physical barrier repair cannot effectively suppress the underlying persistent inflammatory response. While conventional anti-inflammatory ingredients can temporarily inhibit inflammation, they cannot provide the necessary material support for the reconstruction of the damaged barrier, resulting in slow onset of action and frequent recurrence of problems. On the other hand, current formulation systems lack effective mechanisms that can simultaneously and synergistically act on both the "inflammatory response" and "barrier repair" stages. This fragmented approach, targeting individual symptoms separately, cannot effectively address the vicious cycle of skin problems caused by the interplay between the two.
[0006] In summary, existing repair or soothing solutions generally suffer from drawbacks such as a single mechanism of action, low repair efficiency, and difficulty in addressing both the symptoms and the root cause. Due to the lack of a core active ingredient combination with significant synergistic effects, existing technologies typically only target specific localized skin discomfort, limiting their application scenarios and failing to simultaneously meet the comprehensive care needs of complex skin damage conditions. Therefore, there is an urgent need in this field to develop a composition system that can simultaneously address anti-inflammatory and repairing effects, fundamentally break the vicious cycle of inflammation and barrier damage, and possess broader applicability.
[0007] In view of this, the present invention is hereby proposed. Summary of the Invention
[0008] The purpose of this invention is to provide a repair and soothing composition, a repair and soothing product, a preparation method thereof, and an application thereof. The repair and soothing composition, through the significant synergistic effect of mussel extract and recombinant collagen at a specific mass ratio of (12~300):1, simultaneously blocks the vicious cycle of inflammation and barrier damage, achieving both symptomatic and root-cause treatment with highly effective repair and soothing effects that are widely applicable.
[0009] In order to achieve the above-mentioned objectives of the present invention, the following technical solution is adopted: In a first aspect, the present invention provides a repairing and soothing composition comprising mussel extract and recombinant collagen; The mass ratio of the mussel extract to the recombinant collagen is (12~300):1.
[0010] In an optional embodiment, the mass ratio of the mussel extract to the recombinant collagen is (12~300):1; Preferably, the mass ratio of the mussel extract to the recombinant collagen is (30~60):1; More preferably, the mass ratio of the mussel extract to the recombinant collagen is 60:1.
[0011] In an optional embodiment, the mussel extract contains at least 1% DOPA as a percentage of its protein content; and / or, The recombinant collagen has a molecular weight of 25kDa to 35kDa; and / or, The repairing and soothing composition further includes pharmaceutically or cosmetically acceptable excipients; preferably, the excipients include at least one selected from glycerin, p-hydroxyacetophenone, and 1,2-hexanediol; and / or, The repairing and soothing composition has a pH value of 3.7 to 4.7; and / or, The repairing and soothing composition further includes a pH adjuster; wherein the pH adjuster includes citric acid.
[0012] Secondly, the present invention provides a repair and soothing product comprising the repair and soothing composition as described in any of the foregoing embodiments.
[0013] In optional embodiments, the repair and soothing product further includes pharmaceutically or cosmetically acceptable excipients; and / or, The repairing and soothing product is a cosmetic, medical dressing, or topical skin medication; preferably, the dosage form of the cosmetic or medical dressing includes an aqueous solution, serum, lotion, cream, gel, mask, or lyophilized powder; and / or, The pH value of the repair and soothing product is 3.7~4.7.
[0014] Thirdly, the present invention provides a method for preparing the repair and soothing product as described in the foregoing embodiments, comprising the following steps: Mussel extract, recombinant collagen, and pharmaceutically or cosmetically acceptable excipients are mixed. Adjust the pH of the mixture to 3.7-4.7 using an aqueous pH adjuster.
[0015] In an optional embodiment, the pH adjuster comprises citric acid; and / or, the aqueous solution of the pH adjuster has a mass fraction of 1%.
[0016] Fourthly, the present invention also provides the use of the repairing and soothing composition or the repairing and soothing product as described in any of the foregoing claims in the preparation of skin repair or care products for non-disease treatment purposes.
[0017] In an optional embodiment, the skin repair or care product is a cosmetic. The skin repair or care products mentioned herein are cosmetics with soothing, anti-inflammatory, and / or physical barrier repair effects.
[0018] Fifthly, the present invention also provides the use of the repairing and soothing composition or the repairing and soothing product as described in any of the foregoing claims in the preparation of a medicament or medical device for the prevention or treatment of skin inflammation and the promotion of wound healing.
[0019] Compared with existing technologies, the repairing and soothing composition provided by this invention creatively combines mussel extract with recombinant collagen, successfully breaking through the limitations of existing products where a single ingredient can only focus on physical barrier repair or single anti-inflammation. Mussel extract itself has excellent soothing and bioactivity, while recombinant collagen can provide good physical support and moisturizing structure for damaged skin. Combining the two can simultaneously target the two closely related pathological links of "inflammatory response" and "barrier damage," effectively blocking the vicious cycle of skin damage caused by their mutual aggravation.
[0020] Furthermore, by precisely controlling the mass ratio of mussel extract to recombinant collagen within a specific range of (12~300):1, a significant synergistic effect was observed between the two, rather than a simple additive effect. At this specific ratio, the composition not only effectively inhibits the release of various inflammatory factors and quickly soothes redness and swelling in the deeper layers of the skin, but also significantly promotes the adhesion and migration of human cells. This means that while temporarily inhibiting inflammatory signals, the composition can continuously provide the necessary material basis for rebuilding the damaged skin barrier, thereby addressing the shortcomings of slow onset of action and easy recurrence from the source, achieving both symptomatic and root-cause treatment, and providing rapid and lasting repair.
[0021] As is known to those skilled in the art, high concentrations of anti-inflammatory components often inhibit cell migration, while high concentrations of repair-promoting components are significantly less effective in inflammatory environments. Achieving both potent anti-inflammatory and repair-promoting effects with a single formulation is already challenging. Through extensive screening, this invention unexpectedly discovered that mussel extract and recombinant collagen only produce a clear synergistic effect within a specific mass ratio range: in terms of inhibiting inflammatory factors, the reduction is significantly greater than that of either component alone at its highest effective dose; in terms of repair, the cell adhesion and migration rates in the specific ratio group are significantly higher than those of the single component, achieving a two-way optimization of "anti-inflammatory without inhibiting repair, and repair-promoting without promoting inflammation," exceeding the reasonable expectations of those skilled in the art based on the known functions of each component.
[0022] Thanks to the comprehensive and highly effective synergistic repair capabilities brought about by this specific ingredient and its specific ratio, this composition overcomes the common problem of the narrow application range of traditional raw materials. Its excellent anti-inflammatory and soothing dual effects of barrier reconstruction make it not only able to easily deal with daily skin redness and sensitivity soothing, but also capable of handling more complex and demanding care scenarios such as post-minimally invasive repair and deep anti-aging, greatly expanding the application boundaries of the product. Attached Figure Description
[0023] To more clearly illustrate the specific embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the specific embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention. For those skilled in the art, other drawings can be obtained from these drawings without creative effort.
[0024] Figure 1 This is a schematic diagram of the gradient dilution process for the ELISA detection standard in Experimental Example 1 of this invention; Figure 2 This is a statistical graph showing the inhibitory effect of each experimental group sample on the secretion level of the inflammatory factor TNF-α in lipopolysaccharide-induced macrophages (RAW264.7) in Experiment Example 1 of the present invention; Figure 3 This is a statistical graph showing the inhibitory effect of each experimental group sample on the secretion level of the inflammatory factor IL-6 in lipopolysaccharide-induced macrophages (RAW264.7) in Experiment Example 1 of the present invention; Figure 4 This is a statistical graph showing the inhibitory effect of each experimental group sample on the secretion level of the inflammatory factor IL-1β in lipopolysaccharide-induced macrophages (RAW264.7) in Experiment Example 1 of the present invention; Figure 5 This is a statistical chart showing the relative cell adhesion rate of each experimental group sample in Experiment Example 2 of the present invention on the adhesion-promoting effect on human dermal fibroblasts (HDF). Figure 6 This is a microscopic comparison of the effect of each experimental group of samples on promoting the migration of human dermal fibroblasts (HDF) in Experiment Example 3 of the present invention (showing the wound healing situation at 0 hours and 16 hours). Figure 7 In Experiment 3 of this invention, based on Figure 6 A statistical bar chart showing the migration rate of human dermal fibroblasts (HDF) cells for each experimental group, calculated from the scratch test results. Figure 8 The images show the appearance of the repair and soothing product mixture prepared in Example 4 of this invention at the initial preparation stage (D0) (all 4 bottles were at room temperature 25°C). Figure 9 The images show a comparison of the appearance of the repair and soothing product mixture prepared in Experimental Example 4 of this invention after being placed for 14 days (D14) under different environmental conditions (in order: room temperature under light, 4°C without light, 25°C without light, and 45°C without light). Figure 10The images show the appearance of the repair and soothing product mixture prepared in Experimental Example 4 of this invention after being placed for 1 month (D30) under different environmental conditions (light at room temperature 25°C, no light at 4°C, no light at 25°C, and no light at 45°C). Figure 11 Comparison of the appearance and color changes of the mussel extract complex under different pH conditions and storage time; Figure 12 A statistical chart showing the inhibitory effect of each control group and each experimental group after replacing with fish collagen extract on the secretion level of the inflammatory factor TNF-α in macrophages; Figure 13 A statistical chart showing the inhibitory effect of each control group and each experimental group after replacing with fish collagen extract on the secretion level of the inflammatory factor IL-6 in macrophages; Figure 14 A statistical chart showing the inhibitory effect of each control group and each experimental group after replacing with fish collagen extract on the secretion level of the inflammatory factor IL-1β in macrophages; Figure 15 A statistical chart showing the adhesion-promoting effect of each control group and each experimental group after replacing with fish collagen extract on human dermal fibroblasts. Figure 16 A statistical chart showing the migration promotion rate of human dermal fibroblasts by samples from each control group and each experimental group after replacement with fish collagen extract. Figure 17 The scratch test microscopic images show the comparison of the effects of each control group and each experimental group after replacing the sample with fish collagen extract on the migration-promoting effect on human dermal fibroblasts. Detailed Implementation
[0025] The embodiments of the present invention will be described in detail below with reference to examples. However, those skilled in the art will understand that the following examples are for illustrative purposes only and should not be considered as limiting the scope of the invention. Unless otherwise specified in the examples, conventional conditions or conditions recommended by the manufacturer are followed. Reagents or instruments whose manufacturers are not specified are all commercially available conventional products.
[0026] This application provides a repairing and soothing composition, which mainly includes mussel extract and recombinant collagen as core active ingredients.
[0027] In the pathological process that causes skin discomfort, barrier damage and inflammatory response often accompany and exacerbate each other. To effectively break this vicious cycle, the repair and soothing composition in this embodiment combines mussel extract and recombinant collagen in a specific ratio. Mussel extract possesses excellent bioactivity, significantly inhibiting the release of key inflammatory factors such as TNF-α, IL-6, and IL-1β from macrophages, thereby exerting a deep anti-inflammatory and soothing effect. Recombinant collagen provides excellent physical support for damaged tissue, significantly promoting the adhesion and migration of human dermal fibroblasts, and accelerating the physical reconstruction of the damaged skin barrier.
[0028] To ensure a significant synergistic effect between the two components in terms of anti-inflammatory and repair properties, achieving highly effective repair that addresses both the symptoms and the root cause, this embodiment strictly controls the mass ratio of the mussel extract to the recombinant collagen. Specifically, the mass ratio of the mussel extract to the recombinant collagen is limited to (12~300):1.
[0029] Experiments have shown that when the mass ratio is within the above-mentioned range, the anti-inflammatory and cell-repair-promoting effects of the composition exhibit significant statistical differences. The two effects are not simply additive but rather mutually reinforcing. On the one hand, the rapid subsidence of the inflammatory environment provides a favorable microenvironment for collagen to exert its repair function; on the other hand, the health barrier rebuilt by collagen further resists external stimuli, consolidating the anti-inflammatory results. Therefore, this repairing and soothing composition not only has a rapid onset of action but also a long-lasting effect with minimal recurrence, making it widely applicable in various nursing scenarios requiring soothing, anti-inflammatory, and barrier repair.
[0030] In summary, this repairing and soothing composition creatively combines mussel extract and recombinant collagen, strictly controlling their mass ratio within the range of (12~300:1), achieving significant synergistic effects in both anti-inflammatory soothing and barrier repair. At this specific ratio, the two promote each other, simultaneously targeting and blocking the vicious cycle of exacerbating "inflammatory response" and "barrier damage." This composition effectively inhibits the release of inflammatory factors to quickly alleviate skin discomfort, while significantly promoting cell adhesion and migration, providing core material support for the reconstruction of the damaged barrier. This mechanism fundamentally solves the shortcomings of existing ingredients, such as single efficacy, slow onset of action, and easy recurrence, achieving a comprehensive, highly effective, and long-lasting repair effect, while greatly expanding its application potential in various advanced scenarios, from daily soothing to deep repair.
[0031] In a preferred embodiment, in order to further enhance the synergistic effect of the composition in anti-inflammatory and soothing and barrier repair, and to achieve the best dynamic balance in the intervention of the pathological microenvironment, the ratio of the core active ingredients in the composition was precisely optimized.
[0032] Specifically, the mass ratio of the mussel extract to the recombinant collagen is (12~300):1. For example, it can be 12 parts by mass: 1 part by mass, 30 parts by mass: 1 part by mass, 50 parts by mass: 1 part by mass, 80 parts by mass: 1 part by mass, 100 parts by mass: 1 part by mass, 150 parts by mass: 1 part by mass, 200 parts by mass: 1 part by mass, 250 parts by mass: 1 part by mass, 280 parts by mass: 1 part by mass, 300 parts by mass: 1 part by mass, etc. Within this ratio range, the mussel extract can provide a sufficient concentration of active substances to rapidly downregulate the expression of key inflammatory factors in macrophages, clearing obstacles for subsequent repair; at the same time, the relative content of recombinant collagen precisely meets the adhesion and migration requirements of damaged dermal fibroblasts. The two work together to achieve highly efficient barrier remodeling.
[0033] Preferably, to achieve a better state of the synergistic repair microenvironment, the mass ratio of the mussel extract to the recombinant collagen is further defined as (30~60):1. For example, it can be 30 parts by mass: 1 part by mass, 33 parts by mass: 1 part by mass, 36 parts by mass: 1 part by mass, 40 parts by mass: 1 part by mass, 45 parts by mass: 1 part by mass, 48 parts by mass: 1 part by mass, 50 parts by mass: 1 part by mass, 55 parts by mass: 1 part by mass, 58 parts by mass: 1 part by mass, 60 parts by mass: 1 part by mass, etc.
[0034] More preferably, the mass ratio of the mussel extract to the recombinant collagen is 60:1. For example, it can be 60 parts by mass: 1 part by mass, etc. A series of rigorous in vitro cellular efficacy evaluations confirmed that when the system is at this single core ratio, the composition simultaneously reaches peak inhibition rates against inflammatory factors such as TNF-α, IL-6, and IL-1β, as well as peak rates of promoting adhesion and migration of human dermal fibroblasts. At this point, the anti-inflammatory mechanism and the physical reconstruction mechanism are perfectly matched, resulting in not only the most rapid onset of action but also achieving the best symptomatic and root-cause treatment effect on damaged skin. This makes the composition exhibit excellent efficacy in complex application scenarios with high requirements, such as minimally invasive repair.
[0035] In some embodiments, to ensure the bioactivity of the core components in the repair and soothing composition and their long-term stability in the formulation system, the specifications of the raw materials and the physicochemical properties of the system are further defined.
[0036] First, this embodiment screened the physicochemical characteristics of the active components. The dopa content in the mussel extract was limited to no less than 1% of the protein content to ensure sufficient bioadhesion and anti-inflammatory active sites. Simultaneously, recombinant collagen with a molecular weight of 25kDa to 35kDa was selected, aiming to utilize the better biocompatibility of this specific molecular weight range to accelerate cell repair. The molecular weight of the recombinant collagen could be, for example, 25kDa, 26kDa, 28kDa, 30kDa, 31kDa, 32kDa, 33kDa, 34kDa, 35kDa, etc.
[0037] In some embodiments, the repairing and soothing composition further includes pharmaceutically or cosmetically acceptable excipients; preferably, the excipients include at least one of glycerin, p-hydroxyacetophenone, and 1,2-hexanediol.
[0038] To establish a stable application system, the repairing and soothing composition further includes pharmaceutically or cosmetically acceptable excipients. These excipients are selected from at least one of glycerin, p-hydroxyacetophenone, and 1,2-hexanediol, and are used to provide the system with the necessary moisturizing and basic preservative properties.
[0039] The pH value of the repairing and soothing composition is 3.7 to 4.7.
[0040] The repairing and soothing composition further includes a pH adjuster; wherein the pH adjuster includes citric acid.
[0041] Studies have found that the pH of the system has a crucial impact on the synergistic stability of mussel extract and recombinant collagen. In this embodiment, the pH of the repairing and soothing composition is limited to 3.7–4.7. For example, it can be 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.7, etc. Within this pH range, both mussel extract and recombinant collagen maintain optimal conformational stability and antioxidant activity.
[0042] To achieve the aforementioned pH environment, a pH adjuster is added to the composition. This pH adjuster can be selected from inorganic or organic acids, such as hydrochloric acid, lactic acid, and citric acid; preferably, it includes citric acid. By precisely controlling the amount of pH adjuster, the system is maintained within the specific slightly acidic range described above. Experimental results show that the composition, with the specifications and pH environment defined above, exhibits no significant attenuation in its ability to inhibit the release of inflammatory factors and promote fibroblast migration after undergoing high and low temperature cycling and light exposure, demonstrating excellent shelf-life stability and consistent efficacy.
[0043] This application also provides a repair and soothing product comprising the repair and soothing composition as described in any of the foregoing embodiments.
[0044] In practical applications, this product utilizes the synergistic mechanism of its two components to simultaneously and efficiently address skin barrier damage and the resulting inflammation. By integrating a specific ratio of mussel extract and recombinant collagen into the product, upon contact with the skin, the mussel extract inhibits the production of inflammatory mediators, rapidly alleviating skin discomfort; simultaneously, the recombinant collagen promotes skin cell regeneration and migration, achieving rapid barrier reconstruction. This "synergistic anti-inflammatory-synchronous repair" mechanism gives the product significant technological advantages in areas such as sensitive skin care and postoperative wound repair.
[0045] To meet the needs of different usage scenarios, this repairing and soothing product can be formulated in various forms. As a cosmetic application, it can be prepared into common dosage forms such as repair serums, soothing creams, and repair masks; as a medical dressing, it can be prepared into medical cold compresses, sprays, or lyophilized powders. During the preparation process, pharmaceutically or cosmetically acceptable excipients can be added to the product as needed to optimize its physicochemical properties or enhance the user experience. Experiments show that repairing and soothing products containing the aforementioned composition, while maintaining system stability, can significantly reduce the level of inflammation in skin tissue and greatly improve wound healing rates, demonstrating excellent clinical and nursing application value.
[0046] In some specific embodiments, to transform the aforementioned repairing and soothing composition into a terminal carrier suitable for direct application or use, a repairing and soothing product comprising the composition is provided. In some embodiments, the repairing and soothing product further includes pharmaceutically or cosmetically acceptable excipients.
[0047] In some embodiments, the repairing and soothing product is a cosmetic, a medical dressing, or a topical skin medication; preferably, the dosage form of the cosmetic or the medical dressing includes an aqueous solution, serum, lotion, cream, gel, mask, or lyophilized powder.
[0048] In some embodiments, the pH value of the repair and soothing product is 3.7 to 4.7.
[0049] Based on the aforementioned excipients, the repairing and soothing product can be formulated as a cosmetic, medical dressing, or topical skin medication. Preferably, the dosage form of the cosmetic or medical dressing includes an aqueous solution, serum, lotion, cream, gel, mask, or lyophilized powder, tailored to different degrees of skin damage and daily care needs. For example, for daily soothing of mild sensitivity, it can be formulated as a lightweight serum or aqueous solution; for severely dry skin with a severely damaged lipid barrier, it can be formulated as a cream with stronger occlusive properties; and for special scenarios requiring high protein activity after minimally invasive surgery, it can be formulated as a sterile lyophilized powder to maximize its repairing efficacy.
[0050] Furthermore, to ensure that the biological activity of the final product does not decrease during long-term storage, and to complement and help rebuild the natural slightly acidic barrier of human skin, this embodiment strictly limits the pH of the final product. The pH value of the repair and soothing product is 3.7~4.7. Since pH is a dimensionless exponent, it represents its acidity or alkalinity value. For example, the pH value of the repair and soothing product can be 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.6, 4.7, etc.
[0051] Experimental test results show that when the pH value of the final product is stable within the above-mentioned range, the product system exhibits no abnormal changes in appearance or odor after long-term light exposure and high-low temperature cycling tests ranging from 4℃ to 45℃. More importantly, under the aforementioned specific acidic environment and various dosage forms, the synergistic repair and anti-inflammatory activities of mussel extract and recombinant collagen are optimally protected, thus ensuring that the product can exert excellent symptomatic and root-cause treatment effects in various complex practical application scenarios.
[0052] In a preferred embodiment, to ensure that the aforementioned formulation containing the core active ingredient maintains a stable appearance and excellent synergistic repair efficacy during long-term storage and use, this application provides a method for preparing the aforementioned repair and soothing product. This method is simple and operates under mild conditions, making it particularly suitable for processing and preparing protein-based active raw materials that are sensitive to pH and temperature. The preparation method includes: Step S1: Mix mussel extract, recombinant collagen, and pharmaceutically or cosmetically acceptable excipients.
[0053] In practice, appropriate mixing equipment can be selected according to the dosage form being prepared (such as aqueous solution, serum, or cream). To ensure that the active ingredients are evenly dispersed and not damaged by mechanical shear forces, it is preferable to fully dissolve or disperse the mussel extract and recombinant collagen in the pre-prepared excipient matrix at a suitable temperature (e.g., room temperature to 45°C) and under gentle stirring.
[0054] Step S2: Adjust the pH of the mixture to 3.7-4.7 using an aqueous pH adjuster solution.
[0055] Because key active groups (such as dopa groups) in mussel extracts are highly susceptible to oxidative failure in unsuitable acidic or alkaline environments, and the conformational stability of recombinant collagen is also highly dependent on the slightly acidic environment of the system, the final pH value of the system must be precisely controlled. In this embodiment, a pH adjuster (preferably an aqueous citric acid solution) is used to adjust and stabilize the pH value of the mixed system to 3.7–4.7. Since pH is a dimensionless exponent, it represents its acidity or alkalinity numerical value. For example, the final pH value after adjustment can be 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.4, 4.5, 4.6, 4.7, etc. Using reagents with certain buffering properties, such as citric acid, not only provides the required free hydrogen ions but also possesses excellent buffering and chelating properties, making the pH value of the entire formulation system less susceptible to fluctuations in the external environment.
[0056] In some embodiments, the pH adjuster comprises citric acid; preferably citric acid; and / or, the aqueous solution of the pH adjuster has a mass fraction of 1%.
[0057] In the acidification step, the pH adjuster aqueous solution (such as citric acid aqueous solution) has a mass fraction of 1%. The core purpose of using a 1% mass fraction citric acid aqueous solution for slow dropwise addition is to avoid instantaneous protein denaturation or flocculation precipitation caused by excessively high local acidity (i.e., local acid shock). The 1% mass fraction citric acid aqueous solution allows for a smooth transition in the system's pH, providing good operational tolerance for accurately locking the target pH value.
[0058] Stability verification results showed that the product system obtained through the above preparation method, especially by precisely adjusting the pH value to 3.7-4.7 using a 1% citric acid aqueous solution, did not exhibit stratification or precipitation after being subjected to multiple harsh conditions including light exposure, refrigeration (4℃), and high temperature (45℃). The odor remained normal, and the pH value remained consistently stable within the target range with minimal fluctuation. This preparation method successfully constructed a microenvironment highly suitable for the coexistence of mussel extract and recombinant collagen, thus ensuring from the process source that the product can exert a long-lasting synergistic effect of anti-inflammation and repair.
[0059] This application also provides the use of a repairing and soothing composition or product as described in any of the foregoing claims in the preparation of skin repair or care products for non-disease treatment purposes.
[0060] In daily life, human skin is often in a sub-healthy state due to seasonal changes, ultraviolet radiation, environmental pollution, or improper skincare habits (such as over-cleansing or frequent use of irritating ingredients). These non-pathological external stimuli easily trigger micro-inflammatory reactions in the skin, leading to symptoms such as redness, dryness, itching, and stinging, accompanied by weakening and damage to the physical barrier, such as the stratum corneum. Because "inflammatory reactions" and "barrier damage" exacerbate each other during the skin's daily stress response, conventional single-function skincare ingredients often fail to fundamentally improve this type of fragile skin.
[0061] In some embodiments, the skin repair or care product is a cosmetic.
[0062] This embodiment utilizes the remarkable synergistic effect of mussel extract and recombinant collagen in a specific ratio, applying it to daily skin repair and maintenance in a non-clinical, non-disease-treatment context. Specifically, the skin repair or care product can be a cosmetic.
[0063] When used as a core active ingredient or formulation in cosmetics, the skin repair or care product is a cosmetic with soothing, anti-inflammatory, and / or physical barrier repair effects. During consumer use of such cosmetics, the mussel extract in the system can rapidly respond to skin stress signals, downregulate the expression levels of related inflammatory factors, thereby exerting highly effective soothing, redness-reducing, and anti-micro-inflammatory effects, providing an immediate calming effect for fragile skin. Simultaneously, recombinant collagen, in a relatively gentle skin microenvironment, can accelerate the remodeling of the skin's surface physical barrier and enhance intercellular adhesion.
[0064] By introducing this technology into cosmetics, the traditional "treat the symptom, not the cause" approach to skincare has been successfully broken. Experiments show that cosmetics containing this composition not only quickly soothe redness and discomfort caused by daily external stimuli, but also continuously provide structural support for the reconstruction of the damaged skin barrier, achieving a comprehensive treatment. This application effectively covers various high-end cosmetic care scenarios, including daily skin stabilization, environmental irritation soothing, and barrier strengthening in advanced anti-aging processes, demonstrating significant commercial value and broad market application prospects.
[0065] This application also provides the use of a repairing and soothing composition or product as described in any of the foregoing claims in the preparation of a medicament or medical device for the prevention or treatment of skin inflammation and the promotion of wound healing.
[0066] In clinical dermatology and surgery, both physical trauma (such as burns, mechanical injuries, and minimally invasive cosmetic surgery) and pathological injuries (such as various types of dermatitis) can trigger inflammatory infiltration and barrier damage in skin tissues. Under these pathological conditions, local macrophages overexpress pro-inflammatory factors such as TNF-α, IL-6, and IL-1β. The persistent inflammatory microenvironment severely hinders the proliferation and migration of fibroblasts, leading to slow wound healing and even the formation of chronic ulcers.
[0067] This embodiment utilizes the synergistic pharmacological effects of the two components in the repair and soothing composition, using them as a core active matrix or active pharmaceutical ingredient in the preparation of medical-grade products. Specifically, this composition can be used to prepare topical medications (such as anti-inflammatory ointments and wound repair gels) or medical devices (such as sterile medical dressings, medical cold compresses, and biological wound dressings).
[0068] When the composition is applied to the aforementioned drugs or medical devices, its mechanism of action includes two synergistic aspects: on the one hand, the mussel extract in the system, as a potent biological anti-inflammatory agent, can rapidly penetrate deep into the lesion, significantly inhibit and downregulate the release levels of key inflammatory factors in macrophages, quickly eliminate local redness, swelling, heat, and pain, and provide an undisturbed microenvironment for tissue regeneration; on the other hand, the recombinant collagen in the system, as an excellent biomedical material, can form a biomimetic matrix network on the wound surface, significantly promote the adhesion and directional migration of human dermal fibroblasts, and accelerate the formation of granulation tissue and the epithelialization process.
[0069] By preparing the aforementioned composition into corresponding drugs or medical devices, the clinical challenge of traditional single-treatment methods failing to simultaneously address deep anti-inflammatory effects and structural remodeling has been successfully overcome. In vitro pharmacological experiments have confirmed that this formulation system exhibits a dual significant effect of targeted anti-inflammatory action and accelerated tissue regeneration. It can not only effectively treat and prevent various acute and chronic skin inflammations but also significantly shorten the wound healing cycle, demonstrating extremely high practical value and translational potential in the fields of clinical wound repair and dermatopathological intervention.
[0070] The present invention will be further illustrated below with specific embodiments. However, it should be understood that these embodiments are merely for the purpose of more detailed illustration and should not be construed as limiting the present invention in any way.
[0071] Preparation before the experiment: I. Experimental Materials: The sources of the core raw materials used in the embodiments and comparative examples of this application are as follows: (1) Mussel extract: purchased from Jingfei Biotechnology, with a dopamine content of not less than 1% of the protein content. In an alternative embodiment, the mussel extract may contain different subtypes (including proteins derived from byssal threads of mussels of types 1-6), and the mussel species include, but are not limited to: marine mussels (such as...) Mytilus edulisBlue mussels Mytilus galloprovincialis Mediterranean mussels Mytilus trossulus Tros mussels Mytilus coruscus Thick-shelled mussels, Perna viridis Green mussels, Perna canaliculus Green-lipped mussels Perna perna Brazilian mussels Brachidontes variabilis Variable mussels Xenostrobus securis Safe mussels Limnoperna fortune Mussels ginseng, Septifer bilocularis Two-chambered mussels, etc.), and freshwater mussels (such as those from the family Musselidae). Unionidae Or similar to the clam family Hyriidae wait).
[0072] (2) Recombinant collagen: The product used is a commercial product of Shenzhen Baiyin Biotechnology Co., Ltd., with a molecular weight of about 30kDa and the product brand name is RC 3C10C.
[0073] II. Grouping of Examples and Comparative Examples: To verify the synergistic effect of the repair and soothing composition of this application, the following examples (formulas A-F) and comparative examples (single ingredients and formula G) are provided: Example 1 (Formula A): Mussel extract 600,000 μg / mL, recombinant collagen 1,000 μg / mL (mass ratio 600:1).
[0074] Example 2 (Formula B): Mussel extract 300,000 μg / mL, recombinant collagen 1,000 μg / mL (mass ratio 300:1).
[0075] Example 3 (Formula C): Mussel extract 60000 μg / mL, recombinant collagen 1000 μg / mL (mass ratio 60:1).
[0076] Example 4 (Formula D): Mussel extract 30000 μg / mL, recombinant collagen 1000 μg / mL (mass ratio 30:1).
[0077] Example 5 (Formula E): Mussel extract 60000 μg / mL, recombinant collagen 5000 μg / mL (mass ratio 12:1).
[0078] Example 6 (Formula F): Mussel extract 60000 μg / mL, recombinant collagen 10000 μg / mL (mass ratio 6:1).
[0079] Comparative Example 1 (single mussel): mussel extract 600,000 μg / mL.
[0080] Comparative Example 2 (single collagen): 10,000 μg / mL of recombinant collagen.
[0081] Comparative Example 3 (Formula G): Mussel extract 10000 μg / mL, recombinant collagen 10000 μg / mL (mass ratio 1:1).
[0082] A blank control (BC), a negative control (NC), and a positive control (PC) were set up to assist in the verification.
[0083] Experimental Example 1: Evaluation of the anti-inflammatory activity of the composition This experiment used a lipopolysaccharide (LPS)-induced inflammation model in mouse macrophages (RAW264.7). The evaluation was conducted by comparing the differences in the levels of inflammatory cytokines TNF-α, IL-6, and IL-1β secreted by RAW264.7 cells after administration of the test substance.
[0084] 1. Experimental Method: An inflammation model of mouse macrophage leukemia cells (RAW 264.7) induced by lipopolysaccharide (LPS) was used.
[0085] The specific steps are as follows: (1) Cell plating: Resuscitate frozen RAW264.7 cells and passage to no more than 10 passages. Plate at 8 × 10⁻⁶ cells / year. 4 Seed cells at a density of 400 μL per well in 24-well plates. Incubate overnight at 37°C with 5% CO2 until cell confluence reaches 45%–60%.
[0086] (2) Sample addition and administration: Discard the culture medium. Add 600 μL of DMEM complete medium to the blank control (BC); add 600 μL of medium containing 1 μg / mL LPS to the negative control (NC); add 600 μL of medium containing 100 μg / mL dexamethasone and 1 μg / mL LPS to the positive control (PC); add working solutions (600 μL per well) prepared with DMEM complete medium containing 1 μg / mL LPS and the corresponding concentration of sample. Incubate overnight at 37℃ and 5% CO2 for 24 h.
[0087] (3) Collection of cell supernatant: 24 hours after adding the sample, the cell culture supernatant was collected, centrifuged at 3000 rpm for 5 min and then used for ELISA detection.
[0088] (4) ELISA detection and standard preparation: TNF-α, IL-6, and IL-1β were detected using the corresponding ELISA kits from Boster. The gradient dilution preparation process for the standards is as follows (the gradient dilution procedure is as follows). Figure 1 As shown): Dilute the 10000 pg / mL standard to the highest concentration of 1000 pg / mL, and then perform serial dilutions.
[0089] (5) ELISA experimental procedure: Add 100 μL of serially diluted standards and samples from each group to the microplate and react at 37°C for 90 minutes; after washing the plate, add biotin-labeled antibody working solution and react at 37°C for 60 minutes; after washing 3 times, add ABC working solution and react at 37°C for 30 minutes; after washing 5 times, add TMB chromogenic solution and react at 37°C in the dark for about 15 minutes; after adding stop solution, immediately measure the OD value at 450 nm using a microplate reader.
[0090] 3. Experimental Results and Analysis: The inhibitory effects of each group on inflammatory factors are shown in Table 1 (corresponding to...). Figure 2 Table 2 (corresponding) Figure 3 ) and Table 3 (corresponding) Figure 4 ).
[0091] Table 1. Inhibitory effects of each group on the inflammatory factor TNF-α in macrophages
[0092] Formulas A, B, C, D, E, and F all significantly inhibited the expression of the inflammatory factor TNF-α in mouse mononuclear macrophage leukemia cells RAW264.7, with formula C showing the best inhibitory effect on the inflammatory factor TNF-α.
[0093] Table 2. Inhibitory effects of each group on the inflammatory factor IL-6 in macrophages
[0094] Formulas A, B, C, D, E, and F all significantly inhibited the expression of the inflammatory cytokine IL-6 in mouse mononuclear macrophage leukemia cells RAW264.7, with formula C showing the best inhibitory effect on IL-6.
[0095] Table 3. Inhibitory effects of each group on the inflammatory factor IL-1β in macrophages
[0096] Formulas A, B, C, D, E, and F all significantly inhibited the expression of the inflammatory cytokine IL-1β in mouse mononuclear macrophage leukemia cells RAW264.7, with formula C showing the best inhibitory effect on the inflammatory cytokine IL-1β.
[0097] Formula C showed the best inhibitory effect on inflammatory factors TNF-α, IL-6 and IL-1β in mouse mononuclear macrophage leukemia cells RAW264.7, which was stronger than that of mussel adhesive protein or collagen alone, and also stronger than other combinations, indicating that the two have a synergistic effect in regulating inflammatory pathways.
[0098] The experimental conclusions are as follows: Examples 1-6 (Formula AF) can all significantly inhibit the expression of inflammatory factors TNF-α, IL-6, and IL-1β. Among them, Example 3 (Formula C, mass ratio 60:1) showed the best inhibitory effect, significantly stronger than single mussel adhesive protein or single collagen, and also stronger than other ratio combinations (such as comparative Example 3, which did not show significant results), indicating that the two have an excellent synergistic effect in regulating inflammatory pathways.
[0099] Experimental Example 2: Evaluation of the composition's ability to promote repair (cell adhesion activity) This experiment aims to investigate the promoting effect of different ratios of the composition on the adhesion activity of human dermal fibroblasts (HDF) in order to evaluate its efficacy in maintaining tissue stability and repairing the skin barrier.
[0100] 1. Experimental Method: (1) Plate coating: Dilute the test substance with D-PBS to the working concentration and add it together with blank control D-PBS into a 48-well plate that has not been treated with tissue culture, 100 μL per well, at least 3 replicates, and place in a refrigerator at 4°C for 24 h.
[0101] (2) Cell digestion and inoculation: a. Take out the cultured human dermal fibroblasts (HDF), carefully discard the supernatant, wash twice with D-PBS warmed at 37°C for 10 min, add 1 mL (10 cm culture dish) of trypsin, and digest in a CO2 incubator at 37°C for 2 min.
[0102] b. Add 3 mL of DMEM complete medium (containing 10% FBS, 1% P / S) to stop digestion, carefully pipette the cells, transfer them to a 15 mL centrifuge tube, centrifuge at 1000 rpm for 3 min, discard the supernatant, add 2 mL of serum-free DMEM medium, carefully pipette the cells to resuspend them, and count them with a cell counter.
[0103] c. Discard any uncoated test material and seed cells into 48-well plates coated with the test material, according to experimental requirements, at a cell density of 3 × 10⁶ cells / well. 4 Add 300 μL of cell suspension to each well. After inoculation, incubate in a CO2 incubator for 1 hour.
[0104] (3) Cleaning unadhered cells: After culturing for 1 hour, aspirate the supernatant and carefully wash the cells 2-3 times with D-PBS until no floating cells are observed under a microscope.
[0105] (4) Cell viability assay: After washing, add 150 μL of DMEM complete medium containing 10% Alamar Blue to each well and incubate in a CO2 incubator for 1–4 h until the solution just turns from blue to red. After incubation, measure the fluorescence value of each well with a microplate reader. Excitation light: 560 nm, absorption light: 590 nm.
[0106] 5. Calculate the relative cell adhesion rate: Relative cell adhesion rate = (fluorescence value of experimental group - fluorescence value of blank well) / (fluorescence value of blank control group - fluorescence value of blank well) × 100%.
[0107] 2. Experimental Results and Analysis: Table 4. Adhesion-promoting effects of each group on human dermal fibroblasts (corresponding to...) Figure 5 )
[0108] Formulas A, B, C, D, E, F, and G all significantly promoted the adhesion of human dermal fibroblasts (HDF), with formula C showing the best adhesion-promoting effect on HDF.
[0109] Experimental conclusion: All examples and comparative examples can promote HDF cell adhesion, but Example 3 (Formula C) has the most significant adhesion-promoting effect, with a relative cell adhesion rate as high as 262.06%, demonstrating the best synergistic repair-promoting ability.
[0110] Experimental Example 3: Evaluation of the composition's ability to promote repair (cell migration activity / scratch assay) This experiment used the artificial scratch method to monitor the entry of HDF cells into the blank scratch area, simulating the healing and cell migration process of micro-wounds in vivo, and evaluating the wound healing and repair efficacy of the composition.
[0111] 1. Experimental Method: (1) Cell digestion and inoculation: a. Take out the cultured human dermal fibroblasts (HDF), carefully discard the supernatant, wash twice with D-PBS warmed at 37°C for 10 min, add 1 mL (10 cm culture dish) of trypsin, and digest in a CO2 incubator at 37°C for 2 min.
[0112] b. Add 3 mL of LDM complete medium (containing 10% FBS and 1% P / S) to stop digestion, carefully pipette the cells, transfer them to a 15 mL centrifuge tube, centrifuge at 1000 rpm for 3 min, discard the supernatant, add 2 mL of LDM complete medium, carefully pipette the cells to resuspend them, and count them with a cell counter.
[0113] c. Dilute HDF cells to 7 × 10⁶ using DMEM complete culture medium.4 Cells were counted at 3.5 × 10⁶ cells / mL. The cell suspension was then seeded into 48-well plates, with 500 μL of cell suspension added to each well, resulting in a cell density of 3.5 × 10⁶ cells / mL. 4 Cells / well. After inoculation, incubate in a CO2 incubator for 24±2 hours.
[0114] (2) Scratching: When the cell plating rate reaches about 90%, use a 1mL pipette tip to scratch the plate. During the scratching process, the pipette tip should be slightly tilted to the flat surface, and the pipette tip should be used evenly to scratch the bottom of the plate. After scratching, gently wash the plate 2-3 times with D-PBS to remove floating cells.
[0115] (3) Photograph recording: Immediately after the scratch is completed, take a 0h photograph to record the original scratch size. After taking the photograph, remove the D-PBS, add 400μL of serum-free DMEM medium containing the corresponding concentration of sample to each well (at least 3 replicates per group), and put it back into the incubator to continue incubation for 16h. After incubation, take a 16h photograph at the same location using the same magnification objective lens as the observation point taken at 0h, and record the scratch repair status.
[0116] Sample group: Dilute with serum-free DMEM medium to the corresponding concentration and add 400 μL of serum-free DMEM medium containing the corresponding concentration of sample to each well.
[0117] Blank control group: Add 400 μL of serum-free DMEM medium to each well.
[0118] (4) Results Analysis: Use ImageJ software to calculate the scratch area. Drag in the image to be calculated and execute the following commands: Image-Type-8-bit black and white conversion; Process-Smooth image smoothing; Process-Findedges to enhance edge display; Process-Filters-GaussianBlur (Sigma value can be set manually, 4 is recommended) to blur the image; Image-Adjust-Threshold to set the image threshold until the blank area and cell area can be clearly distinguished. The same threshold should be used for images in the same batch of experiments; Open the Magic Wand tool in the toolbar, select the blank area, and delete unnecessary points inside until the entire blank area is selected; Analyze-Measure to obtain the area value. When processing different scratch images, the same parameters should be used, or minor adjustments should be made according to the characteristics of the image to ensure the reproducibility and comparability of the area calculation results.
[0119] Calculate the migration rate for each observation point, in percentage. Perform data filtering, removing outliers while retaining at least three valid migration rate values. Calculate the migration rates for the sample group and the control group, and calculate the p-value of the migration rate for each group relative to the control group. Migration rate % = (0h scratch area) (16h scratch area) / 0h scratch area × 100.
[0120] 2. Experimental Results and Analysis: The actual microscopic observation results of the scratch healing process of human dermal fibroblasts (HDF) in each group of samples are as follows: Figure 6 As shown.
[0121] Combination Figure 6 The direct microscopic images show that, from 0 to 16 hours after scratch formation, the cell edges of the blank control group (BC) migrated inward at a relatively slow rate; in contrast, all experimental groups treated with the sample exhibited varying degrees of cell migration promotion. The single-component groups (mussel extract or collagen) showed limited scratch healing, while the scratch blank area in Example 3 (formula C group) significantly shrank after 16 hours, indicating that cells had essentially completed dense migration and filling towards the scratch center, visually demonstrating the best wound healing promotion effect.
[0122] To further quantify the above-mentioned cell migration-promoting effects, the scratch area of each group was calculated using ImageJ software to obtain specific cell migration rate data. The results are shown in Table 5. Figure 7 As shown: Table 5. The effect of each group on the migration-promoting effect of HDF on human dermal fibroblasts (corresponding to...) Figure 7 )
[0123] Formulas A, B, C, D, E, and F all showed significant migration-promoting effects on human dermal fibroblasts, with Formula C showing the best effect.
[0124] Conclusion: Examples 1-6 all exhibited significant migration-promoting effects, effectively simulating the in vivo wound healing process. Among them, Example 3 (Formula C) showed the best migration-promoting effect, with a migration rate of 87.87%, far exceeding that of the single-component and comparative examples, confirming its excellent physical barrier repair capabilities.
[0125] Experiment Example 4: Study on the Manufacturing Process and Stability of the End Product This embodiment provides a method for preparing a final product formulation mixture containing a specific ratio of mussel extract and collagen, and examines its long-term stability under different storage conditions.
[0126] 1. Preparation method: (1) Place 0.5% p-hydroxyacetophenone and 0.5% 1,2-hexanediol into a sterile container and heat to 60-65℃ to completely dissolve them for later use.
[0127] (2) Add water to the solution container, add glycerin and stir evenly at a speed of 150r / min-300r / min.
[0128] (3) Add the preservative system dissolved in step (1), stir evenly, and after cooling to below 40°C, add mussel extract and RC3C10C recombinant collagen in sequence, stir evenly, and test the initial pH value.
[0129] (4) Add the pre-prepared 1% citric acid aqueous solution to the above system in small amounts several times until the pH value of the final solution stabilizes between 3.7 and 4.7.
[0130] 2. Stability test results: To investigate the physicochemical stability of the product system prepared by the above process under extreme storage conditions and to ensure the long-term synergistic activity of the two-component proteins, an accelerated stability study was conducted on the prepared product (product number: BY250516WY02, initially measured as a colorless and transparent liquid with no characteristic odor and an initial pH of 3.90) for one month.
[0131] The specific stability test conditions are shown in Table 6: Table 6. Stability Test Conditions
[0132] After the above-mentioned periodic investigation, the comprehensive stability test results of the terminal formulation system under various conditions are shown in Table 7: Table 7. Summary of Stability Test Results
[0133] 3. Details of stability monitoring at each time point (mutual verification of charts): In order to further explain the stability of each stage in Table 7 above, the appearance and specific physicochemical parameters of each group of samples were extracted at the beginning (D0), day 14 (D14), and month 1.
[0134] (1) Initial (D0) monitoring results: The freshly prepared mixture sample was retained for observation, and its initial state was as follows: Figure 8 As shown. Figure 8 In the middle, from left to right, are light exposure, -18℃, 25℃, 45℃, pH 3.9, and it is a colorless, transparent, and clear liquid.
[0135] (2) Monitoring results at monitoring point D14 (14 days): After the samples were placed under light, refrigeration (4℃), room temperature (25℃), and high temperature (45℃) conditions for 14 days, they were taken out for testing. The specific physicochemical indicators are shown in Table 8, and the corresponding appearance is as follows. Figure 9 As shown. From left to right, the temperatures are: ambient temperature (25℃) under light, 4℃ without light, 25℃ without light, and 45℃ without light.
[0136] Table 8. Specific monitoring results of monitoring point D14 (14 days)
[0137] Combined with Table 8 Figure 9 It can be seen that after enduring 14 days of extreme temperature and light challenges, the appearance (OK) and odor (OK) of the samples under all conditions remained normal, and no protein precipitation, turbidity or discoloration occurred; and the pH value of each group remained between 3.85 and 3.92 with minimal fluctuation.
[0138] (3) Monitoring results at the monitoring point for 1 month (30 days): After the samples were placed under the above four conditions for 1 month, they were taken out for final testing. The specific physicochemical indicators are shown in Table 9, and the corresponding appearance is as follows. Figure 10 As shown. From left to right, the temperatures are: ambient temperature (25℃) under light, 4℃ without light, 25℃ without light, and 45℃ without light.
[0139] Table 9. Specific monitoring results of monitoring point D30 (1 month)
[0140] Combined with Table 9 Figure 10 It can be seen that even under conditions of prolonged exposure to light and accelerated aging at 45°C for up to one month, the samples still maintained a clear and transparent appearance (OK) and a normal odor (OK). Of particular note is that the pH value of all samples remained stable between 3.88 and 3.92.
[0141] 4. Conclusion of stability test: Combine Tables 6 to 9 and Figures 8-10 The test results clearly demonstrate that the formulation system containing mussel extract and recombinant collagen, prepared using the specific preparation process described in this application (especially the precise pH adjustment to 3.7-4.7 using 1% citric acid), exhibits extremely excellent stability under various harsh conditions, including light, low temperature (4°C), room temperature (25°C), and high temperature (45°C). This specific slightly acidic microenvironment successfully overcomes the technical challenge of easy inactivation and precipitation in protein complex systems, ensuring the long-term synergistic effect of the composition of this invention from a formulation perspective.
[0142] 5. Comparative verification of key physicochemical parameters: To further verify the necessity and technical effectiveness of limiting the specific pH value (3.7~4.7) in this invention, the following comparative examples were set up in this experimental example to accelerate stability and appearance observation: Comparative Example 4 (Neutral pH Environment Comparative Example): The same raw material formula and preparation process as the aforementioned end product mixture were used. The only difference was that the final pH value of the system was adjusted to 6.5 (close to neutral) in the acidification step.
[0143] Comparative test results and analysis: The mixture of Comparative Example 4 was tested at both room temperature and 45°C. The results showed that: To scientifically quantify and demonstrate the necessity of strictly limiting the system pH to between 3.7 and 4.7 in this application, this experiment monitored the appearance color and residual rate of the core active ingredient, DOPA, under different pH conditions (pH 4.5, pH 5.5, pH 6.5) and different storage challenges over a 90-day observation period. The comparison results of sample appearance color changes under different pH conditions are as follows: Figure 11 As shown in Table 15, the specific quantitative determination data of DOPA content changes are summarized in Table 15.
[0144] Table 10. Results of changes in DOPA content in mussel extract under different pH conditions and storage time.
[0145] Combined with Table 10 and Figure 11 The changing appearance trends lead to a highly convincing conclusion: the pH protection range of this invention has a clear technical threshold. At time D0, the dopa content was at a high activity level of 3.49% under all three pH conditions. However, in Comparative Example 4 (neutral pH 6.5), which was removed from the slightly acidic protective environment of this invention, the dopa group underwent severe auto-oxidative degradation: after 30 days of storage at room temperature in the dark, the dopa content had degraded to 0.82%, and after 90 days, it was only 0.11% (almost completely inactivated), accompanied by a significant change in solution color to dark brown / dark yellow.
[0146] In contrast, the pH 4.5 sample within the scope of protection of this invention exhibited extremely impressive antioxidant stability. Even after being stored at room temperature in the dark for up to 90 days, the dopa content remained stable at an ultra-high activity level of 2.79%, and the solution remained colorless, clear, and transparent throughout.
[0147] This not only proves that the slightly acidic range of 3.7 to 4.7 is an indispensable technical means to lock in the activity of the core ingredient "dopa group", but also completely breaks the inherent technical prejudice that "cosmetics are only normal and mild in a neutral environment", and has an extremely high unexpected technical stability effect.
[0148] The aforementioned comparative experiments fully demonstrate that the specific pH range of 3.7 to 4.7 specified in this application is not a conventional or arbitrary choice in the field, but rather a necessary technical feature for maintaining the stability of the mussel extract and recombinant collagen compound system and preventing its inactivation, discoloration, and precipitation. In actual processes, regardless of the conventional pH adjuster used, as long as the system is precisely controlled within this slightly acidic range, unexpected long-term stable effects can be obtained.
[0149] Experiment Example 5: Comparative Verification of Core Active Ingredient Replacement (Comparison with Natural Animal-Derived Fish Collagen Extract) To further verify the irreplaceable inventiveness of the present invention, which combines recombinant collagen of a specific molecular weight with mussel extract, this experimental example replaces the recombinant collagen in the composition of the present invention with a common animal-derived crude extract (fish collagen extract) disclosed in the prior art. The anti-inflammatory activity, cell adhesion promotion and cell migration promotion effects were compared and verified strictly according to the same methods and conditions described in Experimental Examples 1, 2 and 3 above. 1. Experimental Group Design: All other formulation components and experimental conditions were kept completely consistent, except that the "recombinant collagen (RC 3C10C)" in formulations A through G was replaced with an equal amount of commercially available "fish collagen extract". The specific concentration distribution of active ingredients in each group is shown in Tables 11 through 15 below. 2. Experimental Results and Analysis: (1) Comparison of anti-inflammatory activity data: After replacing with fish collagen extract, the inhibitory effects of each formulation group on the secretion of three key inflammatory factors TNF-α, IL-6 and IL-1β in mouse mononuclear macrophage leukemia cells RAW264.7 changed drastically. The specific test data are shown in Table 11 (corresponding to Figure 12 Table 12 (corresponding) Figure 13 ) and Table 13 (corresponding) Figure 14 ).
[0150] Table 11. Inhibitory effect of fish collagen replacement group on TNF-α, an inflammatory factor in macrophages.
[0151] Table 12. Inhibitory effect of fish collagen replacement group on inflammatory cytokine IL-6 in macrophages
[0152] Table 13. Inhibitory effect of fish collagen replacement group on IL-1β inflammatory cytokine in macrophages
[0153] Analysis of the data in Tables 11-13 shows that when the recombinant collagen in the system of this application was replaced with ordinary animal-derived fish collagen extract, its anti-inflammatory synergistic effect completely disappeared. Formulation C (mass ratio 60:1), which originally showed the best inhibitory effect in Experimental Example 1 of this invention, exhibited significantly increased average levels of TNF-α, IL-6, and IL-1β to 47714.705 pg / mL, 4646.1540 pg / mL, and 98.6923 pg / mL, respectively, after the fish collagen extract was replaced, and all of its p-value statistical evaluations became "NS (no significant difference)". This strongly suggests that ordinary animal-derived fish collagen not only fails to produce any anti-inflammatory synergy with mussel extract, but also, due to its complex composition and the influence of impurities, weakens or interferes with the original anti-inflammatory activity of mussel extract to some extent. (2) Comparative data results of promoting repair (cell adhesion and migration): The effects of fish collagen replacement on the adhesion and directional migration activities of human dermal fibroblasts (HDF) were further investigated. The quantitative test results are shown in Table 14 (corresponding to...). Figure 15 Table 15 (corresponding) Figure 16 Actual scratch microscopic observation effect as follows Figure 17 As shown.
[0154] Table 14. Effects of fish collagen replacement group on promoting adhesion of human dermal fibroblasts
[0155] Table 15. The effect of fish collagen replacement group on the migration-promoting effect of human dermal fibroblasts (HDF).
[0156] Combine Table 14 and Table 15 with Figure 17 Microscopic images clearly show that after switching to ordinary animal-derived fish collagen extract, its ability to promote the repair of damaged barriers (adhesion and migration) plummeted. In the original, best-performing golden ratio formula C (60:1), its relative cell adhesion rate was only 123.4774% (far lower than the original recombinant collagen group's 262.06%), while the cell migration rate was even lower at only 35.3167% (compared to the original recombinant collagen group's 87.87%). It even showed a negative inhibitory trend, lower than the blank control group (BC 41.3909%), and a large proportion of the core proportion of P-values completely degenerated to NS.
[0157] 3. Summary of this experiment: In summary, the comparative experimental data strongly demonstrate that the animal-derived crude extract mixture (fish collagen / salmon skin extract) obtained by conventional pepsin hydrolysis disclosed in the prior art, due to its uncertain and non-uniform fragment structure, cannot produce any technical synergy when combined with the highly active mussel extract specific in this application. In fact, it even produces the opposite mechanism of interference on the surface of damaged tissue. This invention, by precisely defining "recombinant collagen" with a molecular weight in the range of 25kDa to 35kDa and at a specific mass ratio, can surpass conventional technical expectations and exert an unexpected synergistic effect by effectively blocking the vicious cycle of "inflammation-barrier damage."
[0158] Example 6: A Repairing and Soothing Sterile Lyophilized Powder Formulation This embodiment provides a highly active lyophilized powder formulation suitable for minimally invasive surgery. The raw materials for its preparation include: 6.0 g of mussel extract (DOPA content ≥1%), 0.1 g of recombinant collagen (RC 3C10C), 40 g of mannitol, 10 g of trehalose, and an appropriate amount of water for injection.
[0159] Preparation process: Mannitol and trehalose were dissolved in an appropriate amount of water for injection and stirred until homogeneous. Mussel extract and recombinant collagen were added, and the pH was adjusted to approximately 4.0 using a trace amount of 1% citric acid aqueous solution. The volume was then brought to 1000 mL with water for injection. After sterile filtration through a 0.22 μm microporous membrane, the solution was dispensed into vials (1 mL / vial). The vials were then placed in a freeze dryer and subjected to pre-freezing, sublimation drying, and desorption drying. The vials were then sealed to obtain the repairing and soothing sterile lyophilized powder. This lyophilized powder exhibits good resolubility and can maintain the dual synergistic activity of the protein components to the greatest extent possible.
[0160] Example 7: A repairing and soothing gel (or medical dressing) This embodiment provides a gel formulation suitable for daily sensitive skin repair and minor wound protection. Its preparation ingredients include: 0.6 g mussel extract, 0.01 g recombinant collagen, 5 g carbomer (or sodium hyaluronate), 50 g glycerin, 5 g p-hydroxyacetophenone, 5 g 1,2-hexanediol, and deionized water to a final volume of 1000 g.
[0161] Preparation process: Carbomer / sodium hyaluronate is dispersed in an appropriate amount of deionized water and fully swollen; dissolved glycerin, p-hydroxyacetophenone, and 1,2-hexanediol solution are added; after the system cools to room temperature, mussel extract and recombinant collagen are slowly added; finally, an appropriate amount of 1% citric acid aqueous solution (or a very small amount of triethanolamine) is used to precisely adjust the pH of the system to between 3.7 and 4.7, and the mixture is stirred until a uniform and transparent gel is formed. This gel has excellent spreadability and can form a good physical protective film on its surface, working synergistically with the underlying layers to exert a long-lasting anti-inflammatory effect.
[0162] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features therein. Such modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. A repairing and soothing composition, characterized in that, Including mussel extract and recombinant collagen; The mass ratio of the mussel extract to the recombinant collagen is (12~300):1; the dopa content in the mussel extract is not less than 1% of the protein content. The molecular weight of the recombinant collagen is 25kDa~35kDa; The pH value of the repairing and soothing composition is 3.7 to 4.
7.
2. The repairing and soothing composition as described in claim 1, characterized in that, The repairing and soothing composition further includes pharmaceutically or cosmetically acceptable excipients; wherein the excipients include at least one of glycerin, p-hydroxyacetophenone, and 1,2-hexanediol.
3. The repairing and soothing composition as described in claim 1, characterized in that, The repairing and soothing composition further includes a pH adjuster; wherein the pH adjuster includes citric acid.
4. A repairing and soothing product, characterized in that, It comprises the repairing and soothing composition as described in any one of claims 1-3.
5. The repairing and soothing product as described in claim 4, characterized in that, The repair and soothing products also include pharmaceutically or cosmetically acceptable excipients; and / or, The repairing and soothing products are cosmetics, medical dressings, or topical skin medications; and / or, The pH value of the repair and soothing product is 3.7~4.
7.
6. A method for preparing the repairing and soothing product as described in claim 4 or 5, characterized in that, Includes the following steps: Mussel extract, recombinant collagen, and pharmaceutically or cosmetically acceptable excipients are mixed. Adjust the pH of the mixture to 3.7-4.7 using an aqueous pH adjuster.
7. The method for preparing the repair and soothing product as described in claim 6, characterized in that, The pH adjuster includes citric acid; and / or, the aqueous solution of the pH adjuster has a mass fraction of 1%.
8. The use of a repairing and soothing composition as described in any one of claims 1-3, or a repairing and soothing product as described in any one of claims 4-5, in the preparation of skin repair or care products for non-disease treatment purposes.
9. The application as described in claim 8, characterized in that, The skin repair or care products mentioned are cosmetics; The skin repair or care products mentioned herein are cosmetics with soothing, anti-inflammatory, and / or physical barrier repair effects.
10. The use of a repairing and soothing composition as described in any one of claims 1-3, or a repairing and soothing product as described in any one of claims 4-5, in the preparation of a medicament or medical device for the prevention or treatment of skin inflammation and the promotion of wound healing.
